Sign inCreate account

Report workspace tools

NCT02720042COMPLETEDanonymous

A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Sponsor

Source record

C. R. Bard

Phase

Source record

Post-Market

Modality

AI-normalized

medical device

Target

AI-normalized

Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Indication / condition

AI-normalized

Hernia

Intervention

Source record

Phasix™ Mesh

Source & freshness

Source record

NCT ID

NCT02720042

Original source

ClinicalTrials.gov

Source last updated

Sep 25, 2020

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02720042

Title

A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Sponsor

C. R. Bard

Status

COMPLETED

Phase

Post-Market

Condition raw

Hernia

Condition normalized

Hernia

Modality raw

Hernia

Modality normalized

medical device

Target raw

Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Target normalized

Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Interventions

Phasix™ Mesh

Public preview

Source record

C. R. Bard conducted a clinical trial to assess the safety and performance of Phasix™ Mesh in treating VHWG Grade 3 midline hernias. The study enrolled 84 patients across 12 sites in Europe, with a focus on long-term outcomes over 24 months.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02720042

Status

COMPLETED

Phase

Post-Market

Sponsor

C. R. Bard

Executive brief

Investment-Ready Snapshot

C. R. Bard conducted a clinical trial to assess the safety and performance of Phasix™ Mesh in treating VHWG Grade 3 midline hernias. The study enrolled 84 patients across 12 sites in Europe, with a focus on long-term outcomes over 24 months.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 25, 2020
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02720042

Indication

Hernia

Modality

medical device

Target

Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Intervention

Phasix™ Mesh

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.